204 related articles for article (PubMed ID: 32202078)
1. Ammonium tetrathiomolybdate in the decoppering phase treatment of Wilson's disease with neurological symptoms: A case series.
De Fabregues O; Viñas J; Palasí A; Quintana M; Cardona I; Auger C; Vargas V
Brain Behav; 2020 May; 10(5):e01596. PubMed ID: 32202078
[TBL] [Abstract][Full Text] [Related]
2. Comparative assessment of clinical rating scales in Wilson's disease.
Volpert HM; Pfeiffenberger J; Gröner JB; Stremmel W; Gotthardt DN; Schäfer M; Weiss KH; Weiler M
BMC Neurol; 2017 Jul; 17(1):140. PubMed ID: 28732478
[TBL] [Abstract][Full Text] [Related]
3. Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson's disease.
Ziemssen T; Smolinski L; Członkowska A; Akgun K; Antos A; Bembenek J; Kurkowska-Jastrzębska I; Przybyłkowski A; Skowrońska M; Redzia-Ogrodnik B; Litwin T
Acta Neurol Belg; 2023 Jun; 123(3):917-925. PubMed ID: 36098934
[TBL] [Abstract][Full Text] [Related]
4. Optical coherence tomography as a marker of neurodegeneration in patients with Wilson's disease.
Langwińska-Wośko E; Litwin T; Dzieżyc K; Karlinski M; Członkowska A
Acta Neurol Belg; 2017 Dec; 117(4):867-871. PubMed ID: 28488258
[TBL] [Abstract][Full Text] [Related]
5. Large-scale networks changes in Wilson's disease associated with neuropsychiatric impairments: a resting-state functional magnetic resonance imaging study.
Wang A; Dong T; Wei T; Wu H; Yang Y; Ding Y; Li C; Yang W
BMC Psychiatry; 2023 Nov; 23(1):805. PubMed ID: 37924073
[TBL] [Abstract][Full Text] [Related]
6. Brain magnetic resonance imaging and severity of neurological disease in Wilson's disease - the neuroradiological correlations.
Rędzia-Ogrodnik B; Członkowska A; Bembenek J; Antos A; Kurkowska-Jastrzębska I; Skowrońska M; Smoliński Ł; Litwin T
Neurol Sci; 2022 Jul; 43(7):4405-4412. PubMed ID: 35275318
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of neurological Wilson's disease with corpus callosum abnormalities.
Zhou ZH; Wu YF; Cao J; Hu JY; Han YZ; Hong MF; Wang GQ; Liu SH; Wang XM
BMC Neurol; 2019 May; 19(1):85. PubMed ID: 31053106
[TBL] [Abstract][Full Text] [Related]
8. Combined sodium Dimercaptopropanesulfonate and zinc versus D-penicillamine as first-line therapy for neurological Wilson's disease.
Zhang J; Xiao L; Yang W
BMC Neurol; 2020 Jun; 20(1):255. PubMed ID: 32593295
[TBL] [Abstract][Full Text] [Related]
9. Impact of treatment on blood-brain barrier impairment in Wilson's disease.
Misztal M; Członkowska A; Cudna A; Palejko A; Litwin T; Piechal A; Kurkowska-Jastrzębska I
Neurol Neurochir Pol; 2023; 57(4):379-386. PubMed ID: 37526174
[TBL] [Abstract][Full Text] [Related]
10. Plasma neurofilament light chain as a biomarker in Wilson's disease.
Yang J; Huang Z; Yang H; Luo Y; You H; Chen D; Pei Z; Li X
Parkinsonism Relat Disord; 2022 Feb; 95():5-10. PubMed ID: 34942565
[TBL] [Abstract][Full Text] [Related]
11. Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study.
Weiss KH; Askari FK; Czlonkowska A; Ferenci P; Bronstein JM; Bega D; Ala A; Nicholl D; Flint S; Olsson L; Plitz T; Bjartmar C; Schilsky ML
Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):869-876. PubMed ID: 28988934
[TBL] [Abstract][Full Text] [Related]
12. Status epilepticus in Wilson's disease.
Pestana Knight EM; Gilman S; Selwa L
Epileptic Disord; 2009 Jun; 11(2):138-43. PubMed ID: 19473947
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Unified Wilson's Disease Rating Scale (UWDRS) in German patients with treated Wilson's disease.
Leinweber B; Möller JC; Scherag A; Reuner U; Günther P; Lang CJ; Schmidt HH; Schrader C; Bandmann O; Czlonkowska A; Oertel WH; Hefter H
Mov Disord; 2008 Jan; 23(1):54-62. PubMed ID: 17960799
[TBL] [Abstract][Full Text] [Related]
14. Lesions in White Matter in Wilson's Disease and Correlation with Clinical Characteristics.
Wang A; Wei T; Wu H; Yang Y; Ding Y; Wang Y; Zhang C; Yang W
Can J Neurol Sci; 2023 Sep; 50(5):710-718. PubMed ID: 35959686
[TBL] [Abstract][Full Text] [Related]
15. Free water imaging as a novel biomarker in Wilson's disease: A cross-sectional study.
Jing XZ; Li GY; Wu YP; Yuan XZ; Luo XG; Chen JL; Taximaimaiti R; Wang XP; Li JQ
Parkinsonism Relat Disord; 2023 Jan; 106():105234. PubMed ID: 36481719
[TBL] [Abstract][Full Text] [Related]
16. Successful Splenectomy for Hypersplenism in Wilson's Disease: A Single Center Experience from China.
Li LY; Yang WM; Chen HZ; Wu YH; Fang X; Zhang J; Wang Z; Han YS; Wang Y
PLoS One; 2015; 10(4):e0124569. PubMed ID: 25910248
[TBL] [Abstract][Full Text] [Related]
17. Early neurological worsening in patients with Wilson's disease.
Litwin T; Dzieżyc K; Karliński M; Chabik G; Czepiel W; Członkowska A
J Neurol Sci; 2015 Aug; 355(1-2):162-7. PubMed ID: 26071888
[TBL] [Abstract][Full Text] [Related]
18. Practical recommendations and new therapies for Wilson's disease.
Brewer GJ
Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
[TBL] [Abstract][Full Text] [Related]
19. Early neurological deterioration in Wilson's disease: a systematic literature review and meta-analysis.
Antos A; Członkowska A; Smolinski L; Bembenek J; Przybyłkowski A; Skowrońska M; Kurkowska-Jastrzębska I; Litwin T
Neurol Sci; 2023 Oct; 44(10):3443-3455. PubMed ID: 37311952
[TBL] [Abstract][Full Text] [Related]
20. Neuroimaging Correlates of Cognitive Deficits in Wilson's Disease.
Shribman S; Burrows M; Convery R; Bocchetta M; Sudre CH; Acosta-Cabronero J; Thomas DL; Gillett GT; Tsochatzis EA; Bandmann O; Rohrer JD; Warner TT
Mov Disord; 2022 Aug; 37(8):1728-1738. PubMed ID: 35723521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
